Alteration of intravenous nicotine self-administration by opioid receptor agonist and antagonists in rats

Psychopharmacology

Volumn 210, Issue 2, 2010, Pages 211-220

  Ismayilova, Naila ^a   Shoaib, Mohammed ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Naloxone; Naltrindole; Nicotine; Opioids; Rat; Reinforcement; Self administration; U50,488

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR ANTAGONIST; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR; NALOXONE; NALTRINDOLE; NICOTINE; OPIATE AGONIST; OPIATE ANTAGONIST; U 50 488; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SELECTIVITY; DRUG SELF ADMINISTRATION; DRUG TARGETING; MALE; NONHUMAN; PARALLEL DESIGN; PRIORITY JOURNAL; RAT; RAT STRAIN; REINFORCEMENT; SMOKING CESSATION; TOBACCO DEPENDENCE; ANIMAL MODEL; FOOD PREFERENCE;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEEDING BEHAVIOR; MALE; NALOXONE; NALTREXONE; NICOTINE; RATS; RECEPTORS, OPIOID; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; SELF ADMINISTRATION; TOBACCO USE DISORDER;

EID: 77953292110     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-1845-4     Document Type: Article

References (56)

1. Bechara A, van der Kooy D (1985) Opposite motivational effects of endogenous opioids in brain and periphery. Nature 314:533-534
2. Bechara A, Nader K, van der Kooy D (1995) Neurobiology of withdrawal motivation: evidence for two separate aversive effects produced in morphine-naive versus morphine-dependent rats by both naloxone and spontaneous withdrawal. Behav Neurosci 109:91-105
3. Berrendero F, Mendizabal V, Robledo P, Galeote L, Bilkei-Gorzo A, Zimmer A, Maldonado R (2005) Nicotine-induced antinociception, rewarding effects, and physical dependence are decreased in mice lacking the preproenkephalta gene. J Neurosci 25:11031112
4. Butschky MF, Bailey D, Henningfield JE, Pickworth WB (1995) Smoking without nicotine delivery decreases withdrawal, in 12-hour abstinent smokers. Pharmacol Biochem Behav 50:91-96
5. Caggiula AR, Donny EC, White AR, Chaudhri N, Booth S, Gharib MA, Hoffman A, Perkins KA, Sved AF (2001) Cue dependency of nicotine self-administration and smoking. Pharmacol Biochem Behav 70:515-530 (Pubitemid 34131646)
6. Chaudhri N, Caggiula AR, Donny EC, Palmatier MI, Liu X, Sved AF (2006) Complex interactions between nicotine and nonpharmacological stimuli reveal multiple roles for nicotine in reinforcement. Psychopharmacology (Berl) 184:353-366
7. Chiamulera C (2005) Cue reactivity in nicotine and tobacco dependence: a "multiple-action" model of nicotine as a primary reinforcement and as a enhancer of the effects of smokingassociated stimuli. Brain Research Reviews 48:74-97
8. Corrigall WA (1999) Nicotine self-administration in animals as a dependence model. Nicotine Tob Res 1:11-20
9. Corrigall. WA, Coen KM (1989) Nicotine maintains robust selfadministration in rats on a limited-access schedule. Psychopharmacology (Berl) 99:473-478
10. Corrigall WA, Coen KM (1991) Opiate antagonists reduce cocaine but not nicotine self-administration. Psychopharmacology (Berl) 104:167-170
11. Corrigall WA, Herling S, Coen KM (1988) Evidence for opioid mechanisms in the behavioral effects of nicotine. Psychopharmacology (Berl) 96:29-35
12. Corrigall WA, Franklin KB, Coen KM, Clarke PB (1992) The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl) 107:285-289
13. Corrigall WA, Coen KM, Adamson KL, Chow BL, Zhang J (2000) Response of nicotine self-administration in the rat to manipulations of mu-opioid and gamma-amtaobutyric acid receptors in the ventral tegmental area. Psychopharmacology (Berl) 149:107-114
14. David SP, Lancaster T, Stead LF, Evins AE, Cahill K (2009) Opioid antagonists for smoking cessation. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD003086. doi: 10.1002/14651858.CD003086.pub2.
15. DeNoble VJ, Mele PC (2006) Intravenous nicotine self-administration in rats: effects of mecamylamine, hexamethonium and naloxone. Psychopharmacology (Berl) 184:266-272 (Pubitemid 43255842)
16. Di Chiara G, Imperato A (1988a) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. National Academy of Sciences of the United States of America, pp 5274-5278
17. Di Chiara G, Imperato A (1988b) Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244:1067-1080
18. Donny EC, Caggiula AR, Knopf S, Brown C (1995) Nicotine self-administration in rats. Psychopharmacology (Berl) 122:390-394
19. Downs DA, Woods JH (1975) Naloxone as a negative reinforcer in rhesus monkeys: effects of dose, schedule, and narcotic regimen. Pharmacol Rev 27:397-406
20. Downs DA, Woods JH (1976) Morphine, pentazocine and naloxone effects on responding under a multiple schedule of reinforcement in rhesus monkeys and pigeons. J Pharmacol Exp Ther 196:298-306
21. George TP, O'Malley SS (2004) Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 25:42-48 (Pubitemid 38081281)
22. Giovino GA (2002) Epidemiology of tobacco use in the United States. Oncogene 21:7326-7340
23. Goldberg SR, Henningfield JE (1988) Reinforcing effects of nicotine in humans and experimental animals responding under intermittent schedules of i.v. drug injection. Pharmacol Biochem Behav 30:227-234
24. Goldberg SR, Hoffmeister F, Schlichting U, Wuttke W (1971) Aversive properties of nalorphine and naloxone in morphinedependent rhesus monkeys. J Pharmacol Exp Ther 179:268-276
25. Gorelick DA, Rose J, Jarvik ME (1988) Effect of naloxone on cigarette smoking. J Subst Abuse 1:153-159
26. Hahn B, Stolerman IP, Shoaib M (2000) Kappa-opioid receptor modulation of nicotine-induced behaviour. Neuropharmacology 39:2848-2855
27. Hand TH, Koob GF, Stinus L, Le Moal M (1988) Aversive properties of opiate receptor blockade: evidence for exclusively central mediation in naive and morphine-dependent rats. Brain Res 474:364-368
28. Hasenfratz M, Jacober A, Battig K (1993) Smoking-related subjective and physiological changes: pre- to postpuff and pre- to postcigarette. Pharmacol Biochem Behav 46:527-534
29. Heidbreder C, Babovic-Vuksanovic D, Shoaib M, Shippenberg TS (1995) Development of behavioral sensitization to cocaine: Influence of kappa opioid receptor agonists. J Pharmacol Exp Ther 275:150-163
30. Heidbreder C, Shoaib M, Shippenberg TS (1996) Differential role of delta-opioid receptors in the development and expression of behavioral sensitization to cocaine. Eur J Pharmacol 298:207-216 (Pubitemid 26096396)
31. Ise Y, Narita M, Nagase H, Suzuki T (2002) Modulation of kappa-opioidergic systems on mecamylamine-precipitated nicotine-withdrawal aversion in rats. Neurosci Lett 323:164-166 (Pubitemid 34310265)
32. Karras A, Kane JM (1980) Naloxone reduces cigarette smoking. Life Sci 27:1541-1545
33. King AC, Meyer PJ (2000) Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacol Biochem Behav 66:563-572
34. Krishnan-Sarin S, Rosen MI, O'Malley SS (1999) Naloxone challenge in smokers. Preliminary evidence of an opioid component in nicotine dependence. Arch Gen Psychiatry 56:663-668
35. Liu X, Palmatier MI, Caggiula AR, Sved AF, Donny EC, Gharib M, Booth S (2009) Naltrexone attenuation of conditioned but not primary reinforcement of nicotine in rats. Psychopharmacology (Berl) 202:589-598
36. Maisonneuve IM, Archer S, Glick SD (1994) U50, 488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci Lett 181:57-60
37. Manzanares J, Looktagland. KJ, Moore KE (1991) Kappa opioid receptor-mediated regulation of dopaminergic neurons in the rat brain. J Pharmacol Exp Ther 256:500-505
38. Mucha RF, Millan MJ, Herz A (1985) Aversive properties of naloxone in non-dependent (naive) rats may involve blockade of central beta-endorphta. Psychopharmacology (Berl) 86:281-285
39. Nemeth-Coslett R, Griffiths RR (1986) Naloxone does not affect cigarette smoking. Psychopharmacology (Berl) 89:261-264 (Pubitemid 16036174)
40. Paterson NE, Froestl W, Markou. A (2004) The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. Psychopharmacology (Berl) 172:179-186 (Pubitemid 38388767)
41. Pickworth WB, Lee EM, Abreu ME, Umbricht A, Preston KL (2004) A laboratory study of hydromorphone and cyclazocine on smoking behavior in residential polydrug users. Pharmacol Biochem Behav 77:711-715 (Pubitemid 38510282)
42. Portoghese et al (1990) Design of peptidomimetic d opioid receptor antagonists using the message-address concept. J Med. Chem 33:1714
43. Rauhut AS, Dwoskin LP, Bardo MT (2005) Tolerance does not develop to the decrease in nicotine self-administration produced by repeated bupropion administration. Nicotine Tob Res 7:901-907
44. Sannerud CA, Prada J, Goldberg DM, Goldberg SR (1994) The effects of sertraline on nicotine seli-administration and food-maintained responding in squirrel monkeys. Eur J Pharmacol 271:461-469
45. Scott DJ, Domino EF, Heitzeg MM, Koeppe RA, Ni L, Guthrie S, Zubieta JK (2007) Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans. Neuropsychopharmacology 32:450-457 (Pubitemid 46106951)
46. Shippenberg TS, Bals-Kubik R (1995) Involvement of the mesolimbic dopamine system in mediating the aversive effects of opioid antagonists in the rat. Behav Pharmacol 6:99-106
47. Shoaib M (2008) The cannabtaoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats. Neuropharmacology 54:438-444
48. Shoaib M, Schindler CW, Goldberg SR (1997a) Nicotine selfadministration in rats: strain and nicotine pre-exposure effects on acquisition. Psychopharmacology (Berl) 129:35-43 (Pubitemid 27037448)
49. Shoaib M, Thorndike E, Schindler CW, Goldberg SR (1997b) Discriminative stimulus effects of nicotine and chronic tolerance. Pharmacol Biochem Behav 56:167-173
50. Spanagel R, Herz A, Shippenberg TS (1992) Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA 89:2046-2050
51. Stolerman IP, Jarvis MJ (1995) The scientific case that nicotine is addictive. Psychopharmacology (Berl) 117:2-10, discussion 14-20
52. Stolerman IP, Shoaib M (1991) The neurobiology of tobacco addiction. Trends Pharmacol Sci 12:467-473
53. Suarez-Roca, Maixner (1983) Activation of kappa opioid receptors by U-50488H and morphine enhances the release of substance P from, rat trigeminal, nucleus slices. J Pharmacol Exp Ther 264:648
54. Sutherland. G, Stapleton JA, Russell MA, Feyerabend C (1995) Naltrexone, smoking behaviour and cigarette withdrawal. Psychopharmacology (Berl) 120:418-425
55. Walters CL, Cleck JN, Kuo YC, Blendy JA (2005) Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron 46:933-943
56. Wong GY, Wolter TD, Croghan GA, Croghan IT, Offord KP, Hurt RD (1999) A. randomized trial of naltrexone for smoking cessation. Addiction 94:1227-1237